Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aligos Therapeutics Inc. ALGS

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.


Recent & Breaking News (NDAQ:ALGS)

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

GlobeNewswire 6 days ago

Aligos Therapeutics to Announce Second Quarter 2022 Results August 4, 2022

GlobeNewswire July 27, 2022

Aligos Therapeutics Initiates 12-Week Dosing Cohort in Phase 1b Study Evaluating Its Class II Capsid Assembly Modulator, ALG-000184

GlobeNewswire July 25, 2022

Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data in Other Chronic Hepatitis B Programs at the European Association for the Study of the Liver's Digital International Liver Congress(TM) 2022

GlobeNewswire June 22, 2022

Aligos Therapeutics to Participate in Metropolitan AntiViral Drug Accelerator, Recipient of NIH and NIAID Grant to Develop Therapeutics Against Coronaviruses and Pathogens of Pandemic Potential

GlobeNewswire June 6, 2022

Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

GlobeNewswire May 23, 2022

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

GlobeNewswire May 4, 2022

Aligos Therapeutics to Present 28-Day Safety, Efficacy and Pharmacokinetic Data for CAM Drug Candidate ALG-000184 and Nonclinical Data for Two Additional Chronic Hepatitis B Programs at the European Association for the Study of the Liver's International Liver Congress(TM) 2022

GlobeNewswire May 3, 2022

Aligos Therapeutics to Announce First Quarter 2022 Results May 4, 2022

GlobeNewswire April 27, 2022

Aligos Therapeutics Selects Drug Candidate ALG-097558, a Potent Ritonavir-Free Oral Protease Inhibitor for the Treatment and Prevention of COVID-19, to Advance into Development

GlobeNewswire April 4, 2022

Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio

GlobeNewswire March 22, 2022

Aligos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

GlobeNewswire March 10, 2022

Aligos Therapeutics to Announce Fourth Quarter and Full Year 2021 Results March 10, 2022

GlobeNewswire March 2, 2022

Aligos Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

Newsfile February 2, 2022

SHAREHOLDER ALERT: Robbins LLP Investigates Aligos Therapeutics, Inc. (ALGS) on Behalf of Shareholders

Business Wire January 28, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

PR Newswire January 27, 2022

Aligos Therapeutics Begins Dosing in Chronic Hepatitis B Patients in its Phase 1 Antisense Oligonucleotide Study (ALG-020572-401)

GlobeNewswire January 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Aligos Therapeutics, Inc. - ALGS

Newsfile January 25, 2022

ALIGOS ALERT: Bragar Eagel & Squire, P.C. is Investigating Aligos Therapeutics, Inc. on Behalf of Aligos Stockholders and Encourages Investors to Contact the Firm

Business Wire January 21, 2022